Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 782 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Olema Pharmaceuticals, Inc.
Market Cap
$707.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$702.89M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
Market Cap
$714.52M
Gross Margin
60.02%
TTM Avg
59.55%
3Y Avg
55.45%
5Y Avg
55.70%
Market Cap
$717.39M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$718.19M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$688.65M
Gross Margin
-16.57%
TTM Avg
15.14%
3Y Avg
17.91%
5Y Avg
27.64%
Market Cap
$730.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$681.76M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
33.33%
Market Cap
$737.10M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $707.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $702.89M | 100.00% | 141.50% | 99.31% | 94.19% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $714.52M | 60.02% | 59.55% | 55.45% | 55.70% |
| Cytek Biosciences, Inc. (CTKB)vs › | $717.39M | 53.23% | 53.64% | 56.38% | 57.18% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $718.19M | 0.00% | 0.00% | 0.00% | 0.00% |
| Anteris Technologies Global Corp. (AVR)vs › | $688.65M | -16.57% | 15.14% | 17.91% | 27.64% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $730.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | 0.00% | 0.00% | 25.00% | 33.33% |
| Candel Therapeutics, Inc. (CADL)vs › | $737.10M | 0.00% | 0.00% | 25.00% | 50.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $739.61M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
